VIDEO: Surgeon summarizes award-winning abstract presentation on DR treatment
Click Here to Manage Email Alerts
MARCO ISLAND, Fla. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Priya Vakharia, MD, discusses phase 2 data for APX3330 for the treatment of diabetic retinopathy.
The trial did not meet its primary endpoint of two-step reduction on the Diabetic Retinopathy Severity Scale (DRSS). However, the data showed a trend of three-step worsening on the binocular DRSS scale among patients with DR who received placebo compared with those treated with APX3330, Vakharia said.
“This will hopefully guide a phase 3 trial looking at three-step worsening of binocular DRSS as a primary endpoint for these patients to stabilize disease rather than improve disease, which would still be pretty incredible for our diabetic retinopathy patients,” she said.
The abstract for these data was awarded the Joanne Angle Abstract of Distinction Award at the WIO Summer Symposium, according to a press release from Ocuphire Pharma.
Editor's note: The headline for this article was updated on August 30, 2023, to more accurately reflect the content of the video perspective.
References:
- Abstract on ZETA-1 study of APX3330 receives award at Women in Ophthalmology (WIO) Summer Symposium. https://www.ocuphire.com/news-media/press-releases/detail/412/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women.
Published August 28, 2023. Accessed August 28, 2023.
Collapse
Vakharia P. ZETA-1 phase 2 trial safety and tolerability results for APX3330: A novel, oral ref-1 inhibitor for the treatment of diabetic retinopathy. Presented at: Women in Ophthalmology Summer Symposium; Aug. 24-27, 2023; Marco Island, Florida.
Read more about
Click Here to Manage Email Alerts